Canadian Pharmacy is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
|
OTHER
|
PRE-CLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | NDA |
| SINGLE AGENT: RECURRENT TMZ-RESISTANT (MDACC)MGMT-unmethylated GBM |
Pre-clinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
NDA Phase not started
|
| COMBINATION WITH XRT: NEWLY DIAGNOSED (SUN YAT-SEN UNIVERSITY)MGMT-unmethylated GBM |
Pre-clinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
NDA Phase not started
|
| OVARIAN CANCER |
Pre-clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
NDA Phase not started
|
| PEDIATRIC BRAIN TUMOR |
Pre-clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
NDA Phase not started
|
VAL-083 Shows Potential Against Multiple Cancers
Our lead candidate, VAL-083, is a “first-in-class” small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studies in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
Explore Our Scientific Publications & Presentations
Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.
VIEW PUBLICATIONS AND PRESENTATIONS